Striatal dopamine deficiency in parkinson's disease: Role of aging
Identifieur interne : 001B31 ( Main/Corpus ); précédent : 001B30; suivant : 001B32Striatal dopamine deficiency in parkinson's disease: Role of aging
Auteurs : Scherman ; Claire Desnos ; François Darchen ; Pierre Pollak ; France Javoy-Agid ; Yves AgidSource :
- Annals of Neurology [ 0364-5134 ] ; 1989-10.
Abstract
The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [3H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [3H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [3H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [3H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.
Url:
DOI: 10.1002/ana.410260409
Links to Exploration step
ISTEX:4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Striatal dopamine deficiency in parkinson's disease: Role of aging</title><author><name sortKey="Scherman" sort="Scherman" uniqKey="Scherman" last="Scherman">Scherman</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Desnos, Claire" sort="Desnos, Claire" uniqKey="Desnos C" first="Claire" last="Desnos">Claire Desnos</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Darchen, Francois" sort="Darchen, Francois" uniqKey="Darchen F" first="François" last="Darchen">François Darchen</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Clinique Neurologique, CHU Grenoble, Grenoble</mods:affiliation></affiliation></author><author><name sortKey="Javoy Gid, France" sort="Javoy Gid, France" uniqKey="Javoy Gid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/ana.410260409</idno><idno type="url">https://api.istex.fr/document/4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001B31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Striatal dopamine deficiency in parkinson's disease: Role of aging</title><author><name sortKey="Scherman" sort="Scherman" uniqKey="Scherman" last="Scherman">Scherman</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Desnos, Claire" sort="Desnos, Claire" uniqKey="Desnos C" first="Claire" last="Desnos">Claire Desnos</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Darchen, Francois" sort="Darchen, Francois" uniqKey="Darchen F" first="François" last="Darchen">François Darchen</name><affiliation><mods:affiliation>Institut de Biologie Physico‐Chimique, Paris</mods:affiliation></affiliation></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name><affiliation><mods:affiliation>Clinique Neurologique, CHU Grenoble, Grenoble</mods:affiliation></affiliation></author><author><name sortKey="Javoy Gid, France" sort="Javoy Gid, France" uniqKey="Javoy Gid F" first="France" last="Javoy-Agid">France Javoy-Agid</name><affiliation><mods:affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author><author><name sortKey="Agid, Yves" sort="Agid, Yves" uniqKey="Agid Y" first="Yves" last="Agid">Yves Agid</name><affiliation><mods:affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989-10">1989-10</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="551">551</biblScope><biblScope unit="page" to="557">557</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686</idno><idno type="DOI">10.1002/ana.410260409</idno><idno type="ArticleID">ANA410260409</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [3H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [3H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [3H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [3H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Dr Scherman PhD</name><affiliations><json:string>Institut de Biologie Physico‐Chimique, Paris</json:string></affiliations></json:item><json:item><name>Claire Desnos Ms</name><affiliations><json:string>Institut de Biologie Physico‐Chimique, Paris</json:string></affiliations></json:item><json:item><name>François Darchen MD</name><affiliations><json:string>Institut de Biologie Physico‐Chimique, Paris</json:string></affiliations></json:item><json:item><name>Pierre Pollak MD</name><affiliations><json:string>Clinique Neurologique, CHU Grenoble, Grenoble</json:string></affiliations></json:item><json:item><name>France Javoy‐Agid PhD</name><affiliations><json:string>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item><json:item><name>Yves Agid MD, PhD</name><affiliations><json:string>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</json:string></affiliations></json:item></author><articleId><json:string>ANA410260409</json:string></articleId><language><json:string>eng</json:string></language><abstract>The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [3H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [3H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [3H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [3H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.</abstract><qualityIndicators><score>6.772</score><pdfVersion>1.3</pdfVersion><pdfPageSize>576 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>1317</abstractCharCount><pdfWordCount>4396</pdfWordCount><pdfCharCount>26849</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>198</abstractWordCount></qualityIndicators><title>Striatal dopamine deficiency in parkinson's disease: Role of aging</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>ANA</json:string></publisherId><pages><total>7</total><last>557</last><first>551</first></pages><issn><json:string>0364-5134</json:string></issn><issue>4</issue><subject><json:item><value>Original Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8249</json:string></eissn><title>Annals of Neurology</title><doi><json:string>10.1002/(ISSN)1531-8249</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1002/ana.410260409</json:string></doi><id>4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Striatal dopamine deficiency in parkinson's disease: Role of aging</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Striatal dopamine deficiency in parkinson's disease: Role of aging</title><author><persName><surname>Scherman</surname></persName><roleName type="degree">Dr</roleName><note type="correspondence"><p>Correspondence: Institut de Biologie Physico‐Chimique, 13 rue P. et M. Curie, 75005 Paris, France</p></note><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation></author><author><persName><forename type="first">Claire</forename><surname>Desnos</surname></persName><roleName type="degree">Ms</roleName><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation></author><author><persName><forename type="first">François</forename><surname>Darchen</surname></persName><roleName type="degree">MD</roleName><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation></author><author><persName><forename type="first">Pierre</forename><surname>Pollak</surname></persName><roleName type="degree">MD</roleName><affiliation>Clinique Neurologique, CHU Grenoble, Grenoble</affiliation></author><author><persName><forename type="first">France</forename><surname>Javoy‐Agid</surname></persName><roleName type="degree">PhD</roleName><affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</affiliation></author><author><persName><forename type="first">Yves</forename><surname>Agid</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</affiliation></author></analytic><monogr><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="pISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><idno type="DOI">10.1002/(ISSN)1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989-10"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="551">551</biblScope><biblScope unit="page" to="557">557</biblScope></imprint></monogr><idno type="istex">4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686</idno><idno type="DOI">10.1002/ana.410260409</idno><idno type="ArticleID">ANA410260409</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [3H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [3H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [3H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [3H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.</p></abstract><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Original Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1988-08-02">Received</change><change when="1989-03-22">Registration</change><change when="1989-10">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8249</doi><issn type="print">0364-5134</issn><issn type="electronic">1531-8249</issn><idGroup><id type="product" value="ANA"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ANNALS OF NEUROLOGY">Annals of Neurology</title><title type="subtitle">Official Journal of the American Neurological Association and the Child Neurology Society</title><title type="short">Ann Neurol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi origin="wiley" registered="yes">10.1002/ana.v26:4</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="1989-10">October 1989</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="9" status="forIssue"><doi origin="wiley" registered="yes">10.1002/ana.410260409</doi><idGroup><id type="unit" value="ANA410260409"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Original Article</title><title type="tocHeading1">Original Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1989 American Neurological Association</copyright><eventGroup><event type="manuscriptReceived" date="1988-08-02"></event><event type="manuscriptRevised" date="1988-12-13"></event><event type="manuscriptAccepted" date="1989-03-22"></event><event type="firstOnline" date="2004-10-08"></event><event type="publishedOnlineFinalForm" date="2004-10-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.1 mode:FullText source:HeaderRef result:HeaderRef" date="2010-02-23"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-03"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst">551</numbering><numbering type="pageLast">557</numbering></numberingGroup><correspondenceTo>Institut de Biologie Physico‐Chimique, 13 rue P. et M. Curie, 75005 Paris, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANA.ANA410260409.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="7"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="32"></count></countGroup><titleGroup><title type="main" xml:lang="en">Striatal dopamine deficiency in parkinson's disease: Role of aging</title><title type="short" xml:lang="en">Striatal Dopamine Deficiency in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><honorifics>Dr</honorifics><givenNames>Daniel</givenNames><familyName>Scherman</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Claire</givenNames><familyName>Desnos</familyName><degrees>Ms</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>François</givenNames><familyName>Darchen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Pierre</givenNames><familyName>Pollak</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af3"><personName><givenNames>France</givenNames><familyName>Javoy‐Agid</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Yves</givenNames><familyName>Agid</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Institut de Biologie Physico‐Chimique, Paris</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Clinique Neurologique, CHU Grenoble, Grenoble</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([<sup>3</sup>H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [<sup>3</sup>H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [<sup>3</sup>H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [<sup>3</sup>H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [<sup>3</sup>H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Striatal dopamine deficiency in parkinson's disease: Role of aging</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Striatal Dopamine Deficiency in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Striatal dopamine deficiency in parkinson's disease: Role of aging</title></titleInfo><name type="personal"><namePart type="termsOfAddress">Dr</namePart><namePart type="family">Scherman</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation><description>Correspondence: Institut de Biologie Physico‐Chimique, 13 rue P. et M. Curie, 75005 Paris, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claire</namePart><namePart type="family">Desnos</namePart><namePart type="termsOfAddress">Ms</namePart><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">François</namePart><namePart type="family">Darchen</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Institut de Biologie Physico‐Chimique, Paris</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre</namePart><namePart type="family">Pollak</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Clinique Neurologique, CHU Grenoble, Grenoble</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">France</namePart><namePart type="family">Javoy‐Agid</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Agid</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Unité INSERM 289 and Clinique de Neurologie et Neuropsychologie, Hôspital de la Pitié‐Salpêtrière, Paris, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">1989-10</dateIssued><dateCaptured encoding="w3cdtf">1988-08-02</dateCaptured><dateValid encoding="w3cdtf">1989-03-22</dateValid><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">7</extent><extent unit="tables">1</extent><extent unit="references">32</extent></physicalDescription><abstract lang="en">The striatal dopaminergic innervation was investigated postmortem in 49 control and 57 parkinsonian brains by assessing the binding of tritiated α‐dihydrotetrabenazine ([3H]TBZOH), a specific ligand of the vesicular monoamine transporter. The density of [3H]TBZOH binding sites in the caudate nucleus of control subjects decreased significantly with age, suggesting an age‐dependent reduction in striatal dopamine innervation. In contrast, an increase with the age at time of death was observed in patients with Parkinson's disease, although the density of [3H]TBZOH binding sites was subnormal. Mean values represented 26.5% and 12.7% of control values in the caudate nucleus and in the putamen, respectively. The binding of [3H]TBZOH in the caudate nucleus decreased exponentially with the duration of Parkinson's disease. The rate of [3H]TBZOH binding decrease, an index of the rate of striatal dopaminergic denervation, was about twice as high in parkinsonian patients as in controls and was not related to the age at onset of the disease. The data suggest that (1) parkinsonian symptoms appear above a threshold degeneration state corresponding to 50% of the normal innervation at the age of 60, and (2) aging does not play a major role in the process of nigrostriatal neuron degeneration in Parkinson's disease.</abstract><relatedItem type="host"><titleInfo><title>Annals of Neurology</title><subTitle>Official Journal of the American Neurological Association and the Child Neurology Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Ann Neurol.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Original Article</topic></subject><identifier type="ISSN">0364-5134</identifier><identifier type="eISSN">1531-8249</identifier><identifier type="DOI">10.1002/(ISSN)1531-8249</identifier><identifier type="PublisherID">ANA</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>551</start><end>557</end><total>7</total></extent></part></relatedItem><identifier type="istex">4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686</identifier><identifier type="DOI">10.1002/ana.410260409</identifier><identifier type="ArticleID">ANA410260409</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1989 American Neurological Association</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001B31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:4E61EA1160F04E1BDC6B27DB7ECD7C1F4EE67686
|texte= Striatal dopamine deficiency in parkinson's disease: Role of aging
}}
| This area was generated with Dilib version V0.6.23. |  |